Dr BabuRajendra B Naik: Difference between revisions
| Line 61: | Line 61: | ||
* Voglibose efficacy trials | * Voglibose efficacy trials | ||
He has led epidemiological studies on Type 2 diabetes in children and collaborated with ICMR and WHO-affiliated institutions. | He has led epidemiological studies on Type 2 diabetes in children and collaborated with ICMR and WHO-affiliated institutions. | ||
==Publications== | ==Publications== | ||